Apogee Therapeutics Inc (NASDAQ: APGE) on Tuesday, plunged -3.42% from the previous trading day, before settling in for the closing price of $34.55. Within the past 52 weeks, APGE’s price has moved between $32.46 and $72.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 7.88%. With a float of $36.13 million, this company’s outstanding shares have now reached $45.02 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Apogee Therapeutics Inc is 38.25%, while institutional ownership is 83.06%. The most recent insider transaction that took place on Feb 05 ’25, was worth 143,229. In this transaction Chief Medical Officer of this company sold 3,520 shares at a rate of $40.69, taking the stock ownership to the 252,623 shares. Before that another transaction happened on Feb 05 ’25, when Company’s Chief Executive Officer sold 15,000 for $40.58, making the entire transaction worth $608,700. This insider now owns 1,302,987 shares in total.
Apogee Therapeutics Inc (APGE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.88% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
Apogee Therapeutics Inc (APGE) is currently performing well based on its current performance indicators. A quick ratio of 16.39 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -4.32 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Compared to the last year’s volume of 0.54 million, its volume of 0.69 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 18.81%. Additionally, its Average True Range was 2.37.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 2.93%, which indicates a significant decrease from 9.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.25% in the past 14 days, which was lower than the 67.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.92, while its 200-day Moving Average is $47.04. Nevertheless, the first resistance level for the watch stands at $34.47 in the near term. At $35.57, the stock is likely to face the second major resistance level. The third major resistance level sits at $36.34. If the price goes on to break the first support level at $32.60, it is likely to go to the next support level at $31.83. Should the price break the second support level, the third support level stands at $30.73.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
Market capitalization of the company is 1.95 billion based on 45,027K outstanding shares. Right now, sales total 0 K and income totals -83,990 K. The company made 0 K in profit during its latest quarter, and -49,020 K in sales during its previous quarter.
